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OBJECTIVE — To evaluate ethnic differences in medication concerns (e.g., side effects and
costs) that may contribute to ethnic differences in the adoption of and adherence to type 2
diabetes treatments.
RESEARCH DESIGN AND METHODS — We conducted face-to-face interviews from
May 2004 to May 2006 with type 2 diabetic patients 18 years of age (N  676; 25% Latino,
34% non-Hispanic Caucasian, and 41% non-Hispanic African American) attending Chicago-
area clinics. Primary outcomes of interest were concerns regarding medications and willingness
to take additional medications.
RESULTS — LatinosandAfricanAmericanshadhigherA1ClevelsthanCaucasians(7.69and
7.54% vs. 7.18%, respectively; P  0.01). Latinos and African Americans were more likely than
Caucasians to worry about drug side effects (66 and 49% vs. 39%, respectively) and medication
dependency (65 and 52% vs. 39%, respectively; both P  0.01). Ethnic minorities were also
more likely to report reluctance to adding medications to their regimen (Latino 12%, African
American 18%, and Caucasian 7%; P  0.01). In analyses adjusted for demographics, income,
education, and diabetes duration, current report of pain/discomfort with pills (odds ratio 2.43
[95% CI 1.39–4.27]), concern regarding disruption of daily routine (1.97 [1.14–3.42]), and
African American ethnicity (2.48 [1.32–4.69]) emerged as major predictors of expressed reluc-
tance to adding medications.
CONCLUSIONS — Latinos and African Americans had signiﬁcantly more concerns regard-
ing the quality-of-life effects of diabetes-related medications than Caucasians. Whether these
medicationconcernscontributesigniﬁcantlytodifferencesintreatmentadoptionanddisparities
in care deserves further exploration.
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T
ype 2 diabetic patients of racial/
ethnic minorities experience signiﬁ-
cantly higher rates of diabetes-
related complications than non-Hispanic
Caucasians. In population-based studies,
non-Hispanic African Americans have
rates of renal disease, blindness, amputa-
tions, and amputation-related mortality
two to four times greater than those of
Caucasians (1–3). Similarly, Latinos have
higher rates of renal disease and retinop-
athy than Caucasians (1,2,4,5). African
American patients have age-adjusted dia-
betes mortality rates that are approxi-
mately twice those of Caucasians (6). The
elimination of such health disparities is a
major goal of the U.S. preventive health
agenda (7).
Efforts to reduce the burden of diabe-
tes complications have focused on im-
proving the delivery of comprehensive
diabetes care while simultaneously ad-
dressing control of blood glucose, blood
pressure, and cholesterol. Modern dia-
betes care requires greater use of medi-
cations and a standard form of
polypharmacy (8–10). Whereas there is
someevidencethatmorepatientswithdi-
abetes are adopting comprehensive dia-
betes care (11), many recent studies
continuetoshowthatlargeproportionsof
patients with diabetes continue to have
poor glycemic (20%), blood pressure
(33%), and cholesterol (40%) control
(12). Patients’ concerns regarding the
burdens of life with medications may be
key factors to determining patients’ will-
ingness or unwillingness to adopt multi-
ple medications; an unwillingness to
adopt medications may be grounded in
legitimate concerns. Patients’ level of
adoption of multiple medications may, in
turn, inﬂuence the intensity of risk factor
control for the general population and for
racial/ethnicminorities.Insupportofthis
conjecture, a recent study has reported
that racial/ethnic differences in medica-
tionadherenceareamongthemostsignif-
icant independent predictors of
disparities in glycemic control (13).
Whereas patient concerns regarding
the burdens of medications may be a key
determinant of both the intensity of dia-
betes care for the general population and
disparities in care, few studies have di-
rectly examined and quantiﬁed patient
concerns regarding the burdens of daily
diabetes medications across racial/ethnic
groups (14). These concerns may system-
atically differ by race/ethnicity and may
be associated with differential willingness
to adopt more medications. We set out to
determine whether there are racial/ethnic
differences in medication concerns and
the willingness to adopt more medica-
tions among a sample of adults with type
2 diabetes living in the Chicago area.
RESEARCH DESIGN AND
METHODS— FromMay2004toMay
2006, we conducted face-to-face inter-
views with diabetic patients aged 18
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academic medical center (University of
Chicago,Chicago,IL)orphysicianofﬁces
afﬁliated with a suburban hospital (Mac-
Neal Hospital, Berwyn, IL). Before con-
ducting the study, we knew that patients
attending the University of Chicago were
predominately African American,
whereas patients attending MacNeal Hos-
pital were mainly Latino and Caucasian.
To achieve an ethnically diverse study
population, we planned for balanced re-
cruitment from the two sites. We identi-
ﬁed patients using electronic billing data
provided by the clinics. Patients were in-
cluded if they had an ICD-9 billing code
of 250.xx in the past year and were 18
years of age. Physicians at each clinic ap-
proved which patients we were permitted
to contact. We excluded patients with
type 1 diabetes, as well as those who had
dementia during telephone recruitment.
Additional patients were excluded if they
scored 17 points on the Mini-Mental
State Examination (15) during in-person
interviews. Potential subjects were sent
study recruitment letters in random or-
der. Letters were followed by a telephone
call. We successfully contacted 2,990 pa-
tients, 2,398 of whom were determined
eligible for the study. A total of 910 pa-
tients(38%ofeligiblesubjects)scheduled
interviews, and 701 patients (29% of eli-
gible subjects) completed interviews. The
average age and sex distributions of sub-
jects who completed interviews did not
differfromthoseofothereligiblesubjects.
For the purposes of this analysis, we
focused on the 676 patients who identi-
ﬁed themselves as non-Hispanic African
American, non-Hispanic Caucasian, or
Latino. To determine race/ethnicity, we
separately asked patients to identify their
race (e.g., African American, Caucasian,
Asian, Native American) and to identify
themselves as Hispanic, Latino, or Span-
ish. Interviews took approximately 1 h
andwereconductedbytrainedinterview-
ers in English or Spanish. All Spanish in-
terview materials were professionally
translated and back translated. The over-
all survey included an in-depth examina-
tion of health state utilities related to
diabetes treatments and complications
not included in this analysis (16,17).
For the purposes of this analysis, we
focused on the responses to questions re-
garding current and future medications.
The concepts included in the section of
medication concerns were partially
drawnfromtheexistingliterature(18,19)
and were inﬂuenced by our prior qualita-
tive research with older diabetic patients
(20). New questions were developed and
revised in an iterative fashion by the in-
vestigative team with input from pilot
testing with patients. This section in-
cluded statements regarding concerns
aboutcurrentmedicationssuchasanxiety
about side effects, fear of dependency on
medications, need for help taking medi-
cations, concerns regarding medication
costs, and reports of pain or discomfort
related to medication taking. In a similar
question format, patients were also asked
about the implication of changes to their
medicationregimenfortheirdailyroutine
and worries about their health. These
statements referred to patients’ percep-
tions of their overall medication regimen
and not to their diabetes-speciﬁc medica-
tion regimen. Responses to these state-
ments were recorded on a ﬁve-point
Likert scale (“agree strongly,” “agree
slightly,” “neither agree nor disagree,” “dis-
agree slightly,” and “disagree strongly”).
These questions were accompanied
by a series of questions regarding their
willingness to adopt future changes in
treatment regimens. Patients were specif-
ically asked whether they would be will-
ing to take additional medications if told
by their physician that such a change in
their treatment regimen would be beneﬁ-
cial. Among patients currently not taking
insulin, the same question was asked re-
garding the potential addition of insulin.
Responses were recorded as “Yes,” “No,”
or “Don’t know.” These questions were
followed by a series of statements regard-
ing potential concerns regarding the
meaning and consequence of changes in
medications.
We also asked patients a variety of
questions regarding their health-related
qualityoflife(12-itemShort-FormHealth
Survey,Version2[21]),functionalstatus,
currentmedications,anddiabetes-related
complications. We examined medical
records for additional data on comorbidi-
ties (Charlson Comorbidity Index [22])
and current risk factor levels. To assess
thereliabilityofchartabstraction,weper-
formed a 10% re-review. The intraclass
correlation coefﬁcients for A1C, systolic
bloodpressure,andLDLcholesterolwere
0.96, 0.81, and 0.91, respectively. The 
statistic for micro- and cardiovascular
complicationsofdiabeteswas0.79.These
statistics indicate moderate-to-high inter-
rater reliability.
Statistical analysis
All analyses were performed using SAS
statisticalsoftware(Release8.1;SASInsti-
tute, Cary, NC). The major outcomes of
interest were 1) concerns regarding med-
ications and 2) reluctance to add more
medications or insulin; the major predic-
tor of interest was race/ethnicity. For
statements describing concerns for cur-
rent and future medications, we dichoto-
mized Likert scale responses by grouping
responses of “Agree somewhat” and
“Agree strongly” together. For questions
regarding willingness to take additional
medications, we dichotomized responses
into “No” and all other responses. In un-
adjusted analyses, we compared these
proportions using the 
2 test. For ad-
justed analyses, we used logistic regres-
sion. In the adjusted analyses, we
accounted for covariates such as age,
sex, education, income, and duration of
diabetes.
We also examined the interrelation-
ship of concerns regarding medications
and reluctance to add more medications
or insulin. For these analyses, the main
outcome of interest was reluctance to add
more medications. As described above,
we ﬁrst performed unadjusted analyses
examining the relationship between each
oftheconcernsformedicationsandreluc-
tance to add more medications. We then
constructed a multivariable logistic re-
gression model, ﬁrst considering vari-
ables signiﬁcantly associated with
outcomes in univariate analysis, followed
by a search for collinear terms. With this
preliminary model, ethnicity was then
incorporated and evaluated for its effects
as a confounder of medication-concern
variables.
The study protocol was approved by
the University of Chicago and MacNeal
Hospital Institutional Review Boards and
found to be in compliance with human
subject protection and Health Insurance
Portability and Accountability Act
(HIPAA) regulations.
RESULTS— We interviewed 676 pa-
tients who identiﬁed themselves as Cau-
casian(34%),AfricanAmerican(41%),or
Latino (25%) (Table 1). Latino patients
were signiﬁcantly younger (mean age 55
years vs. 65 years for African Americans
and Caucasians; P  0.01), more likely to
have been born outside the U.S. (64% vs.
1 and 7%, respectively; P  0.01), and
less likely to have completed high school
(50% vs. 73 and 84%, respectively; P 
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were conducted in Spanish. The overall
study population was well insured with
overhalfofthepatientshavingsomeform
of private insurance and 90% of pa-
tients having a prescription drug plan.
There was no signiﬁcant difference in
the mean duration of diabetes across eth-
nic groups (9–10 years). However, there
were differences in the prevalence of co-
morbid conditions or complications
across ethnic groups. Latinos had less
self-reported hypertension than African
Americans and Caucasians, but there was
no difference in prevalence of hypercho-
lesterolemia. African Americans had
higher rates of self-reported diabetes
complications such as eye disease, heart
disease, and stroke, whereas Latinos had
the lowest rates. For overall health status,
Latinoshadhighermeanphysicalcompo-
nent summary scores than the other eth-
nic groups but lower mental component
summary scores.
Mean A1C levels were higher for Af-
rican Americans (7.54%) and Latinos
(7.69%) than for Caucasians (7.18%)
(P  0.01); consistent with these differ-
ences, lower proportions of African
Americans (41%) and Latinos (47%) had
A1C levels 7% than of Caucasians
(55%) (P  0.01). With regard to choles-
terol control, Latinos also had the highest
mean LDL cholesterol levels (102 vs. 95
mg/dl) and the lowest proportion of pa-
tients with LDL cholesterol levels 100
Table 1—Demographics and clinical characteristics by race/ethnicity among adults with type 2 diabetes in Chicago-area clinics, 2004–2006
Caucasian
African
American Latino P*
n 230 279 167
Age (years) 65  13 65  13 55  13 0.0001
Male 50 32 48 0.0001
Born outside the U.S. 7 1 64 0.0001
Interview conducted in Spanish 0 0 51 0.0001
High school graduate 84 73 50 0.0001
Health insurance
Private 75 55 69 0.0001
Medicare 50 58 22 0.0001
Medicaid 8 29 16 0.0001
Prescription drug plan 90 93 92 0.6301
Annual income 10,000 USD 11 29 13 0.0001
Duration of diabetes (years) 10  91 0  99  7 0.4631
Self-reported comorbid conditions or complications
Hypertension 72 86 57 0.0001
Hypercholesterolemia 70 62 63 0.1322
Diabetic eye disease 13 22 25 0.0081
Diabetic kidney disease 6 8 10 0.3259
Foot disease (peripheral neuropathy and amputation) 56 54 45 0.0796
Heart disease 33 34 22 0.0258
Stroke 9 16 4 0.0004
SF-12
PCS 42  12 41  12 47  10 0.0001
MCS 51  11 51  11 47  11 0.0004
Risk factor levels†
A1C (%) 7.18  1.45 7.54  1.59 7.69  1.78 0.0057
A1C 7% 55 41 47 0.0057
LDL cholesterol (mg/dl) 93  35 96  32 102  34 0.0090
LDL cholesterol 100 mg/dl 65 61 56 0.1962
Systolic blood pressure (mmHg) 130  16 136  18 126  17 0.0001
Systolic blood pressure 130 mmHg 47 32 54 0.0001
Number of medications‡§ 7  47  35  3 0.0002
Mean number of diabetes-related medications‡ 4  24  23  2 0.0001
Glucose lowering therapy‡
Diet alone 23 19 14 0.0014
Oral medications alone 56 55 68
Insulin and oral medications 8 16 5
Insulin alone 13 11 13
Aspirin‡ 47 43 24 0.0001
Cholesterol lowering drug‡ 68 53 51 0.0006
Data are means  SD or % unless otherwise indicated. *Differences in means were assessed with the Wilcoxon’s rank-sum test; differences in proportions were
assessed with the 
2 test. †Abstracted from medical records. ‡Based on patient self-report. §The most common nondiabetes-related medications included multi-
vitamins, proton-pump inhibitors, calcium supplementation, and thyroid replacement therapy. MCS, mental component summary; PCS, physical component
summary; SF-12, 12-item Short-Form Health Survey.
Huang and Associates
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ethnicgroups(P0.01).Thepicturewas
reversed in the case of blood pressure
control in that Latinos had the lowest
mean systolic blood pressure levels (126
mg/dl) of the three groups, whereas Afri-
can Americans had the highest (136 mg/
dl) (P  0.01).
Consistent with our ﬁndings related
toriskfactorlevels,Latinoshadthelowest
useofmedicationsamongthethreeracial/
ethnic groups: the lowest mean number
of both total medications and diabetes-
related medications (three vs. four medi-
cations for African Americans and
Caucasians; P  0.01). In terms of inten-
sity of glucose control regimen, Latinos
also had the lowest percentage of insulin
use (18%), whereas African Americans
had the highest use of insulin (27%) (P 
0.01). Similarly, Latinos had the lowest
percentage of aspirin prophylaxis use (24
vs. 47% for Caucasians) and cholesterol-
lowering drug use (51 vs. 68% for Cauca-
sians; both P  0.01). Frequently used
nondiabetes medications included multi-
vitamins, proton-pump inhibitors, cal-
cium supplementation, and thyroid
replacement therapy.
In direct questions regarding con-
cerns for medications, both African
Americans and Latinos had signiﬁcantly
more concerns about various elements of
medication-taking than Caucasians (Ta-
ble 2). They were more likely to say that
they worried about side effects (African
Americans49%andLatinos66%vs.Cau-
casians 39%), development of depen-
dency on medications (52% and 65% vs.
39%, respectively), and the potential
harms of generic substitutes (35 and 26%
vs. 13%, respectively; all P  0.01).
Three-quarters of Latinos had concerns
about the costs of medications compared
with one-half of African Americans and
Caucasians(P0.01).Withregardtothe
implications of future changes to medica-
tion regimens, African Americans and
Latinos were also more likely to report
that changes in their medication regimen
would represent a disruption in their
daily routine and would raise concerns
about their health.
When we directly queried patients
about their willingness to adopt more
medications, we found signiﬁcant differ-
ences across racial/ethnic groups. More
African Americans (18%) and Latinos
(12%) than Caucasians would be op-
posed to the addition of more medica-
tions if recommended by their physician
(7%)(P0.01),althoughthemajorityof
patients in all groups would accept such
changes in their medications. When
asked about the possibility of adding in-
sulin(amongthosenotusinginsulin),the
proportion of patients opposed to such a
changewaslargerthantheproportionop-
posed to the general addition of more
medications. As observed with the prior
question, larger proportions of African
Americans(26%)andLatinos(22%)than
Caucasians (17%) were opposed to the
addition of insulin to their regimens (P 
0.09), although this difference did not
reach statistical signiﬁcance.
The majority of these unadjusted ra-
cial/ethnic differences in medication con-
cerns were attenuated by adjustment for
socioeconomic, demographic, and clini-
cal covariates but remained signiﬁcant
(Table 3). For example, the association
between race/ethnicity and side effect
concerns became less pronounced in ad-
justed analysis (for Latinos, unadjusted odds
ratio (OR) 3.00 [95% CI 1.98–4.55] 3 ad-
justed OR 2.92 [1.83–4.64]). With re-
gard to responses to questions regarding
theadditionofmoremedications,African
Americans remained signiﬁcantly more
likely to express a reluctance to add new
medicationsthanCaucasians(unadjusted
OR 3.05 [1.66–5.61] 3 adjusted OR
2.53 [1.35–4.72]) even after adjustment
for socioeconomic, demographic, and
clinical covariates. Latino-Caucasian dif-
Table 2—Differences in medication concerns and perceptions of future medications by race/ethnicity among adults with type 2 diabetes in
Chicago-area clinics, 2004–2006*
Caucasian
African
American Latino P
n 230 279 167
Statements reﬂecting medication concerns (proportion responding afﬁrmatively)
I worry about side effects from my medications. 39 49 66 0.0001
I worry about becoming dependent on my medications. 39 52 65 0.0001
I worry about the expense of my medications or glucose-monitoring supplies. 52 51 71 0.0001
I have problems with my prescription drug plan. 24 24 29 0.4962
I sometimes have difﬁculty remembering to take my medications. 34 34 39 0.5357
I could use another person’s help taking my medications. 15 19 23 0.1570
I ﬁnd taking my pills unpleasant or painful. 12 17 17 0.2819
I ﬁnd taking my insulin unpleasant or painful. 57 (39) 87 (40) 32 (50) 0.5466
If my doctor asked me to change my medication regimen, it would disrupt
my daily routine. 14 18 27 0.0041
If my doctor asked me to change my medication regimen, it would make me
worry more about my health. 22 41 57 0.0001
I worry about switching from name-brand to generic drugs. 13 35 26 0.0001
Willingness to take more medications or insulin (proportion responding “No”)
If your doctor told you that you would beneﬁt from taking more medications,
would you be willing to take more? 7 18 12 0.0008
If your doctor told you that you would beneﬁt from taking insulin, would
you be willing to take insulin? 173 (17) 191 (26) 135 (22) 0.0940
Dataare%orn(%)unlessotherwiseindicated.*Allanalysesperformedusing
2tests.Originalresponsestoquestionsregardingmedicationconcernswereoriginally
onaLikertscale(“agreestrongly,”“agreeslightly,”“neitheragreenordisagree,”“disagreeslightly,”and“disagreestrongly”).Originalresponsestoquestionsregarding
willingness to take more medications were “Yes,” “No,” and “Don’t know.”
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signiﬁcance in unadjusted analysis (1.95
[0.97–3.93]) and became clearly non-
signiﬁcant (1.48 [0.69–3.15]) when
accounting for covariates.
Inourcomprehensiveanalysisofpre-
dictors of a reluctance to add medica-
tions, we found that concerns about
growing dependent on medications, re-
port of unpleasant or painful experience
with medications, anticipated disruption
of daily routine, concerns regarding
health if faced with medication changes,
and concerns over switches from brand-
name to generic drugs were all signiﬁ-
cantly associated with a reluctance to add
more medications (all P  0.01). The pa-
tient’s physical health status, current
number of medications, and current
number of diabetes-related medications
were not signiﬁcantly associated with a
reluctance to add more medications.
Higher mental health status was associ-
ated with a lower likelihood of opposing
additional medications (P  0.01). After
identiﬁcation and exclusion of collinear
variables, the ﬁnal model of a reluctance
to add more medications included report
of unpleasant or painful experience with
medications (OR 2.43 [95% CI 1.39–
4.27]; P  0.01) and anticipated disrup-
tion of daily routine (1.97 [1.14–3.42];
P  0.02). African American race re-
mained a signiﬁcant predictor of reluc-
tance to add more medications even
within the fully adjusted model (2.48
[1.32–4.69]; P  0.01).
CONCLUSIONS — Our study pro-
vides valuable insights into how concerns
regarding quality of life with medications
and the willingness to adopt more medi-
cations vary across type 2 diabetic pa-
tients of various racial/ethnic groups.
Over one-half of racial/ethnic minority
patients in our sample expressed con-
cerns regarding side effects of medica-
tions and the development of possible
dependency on medications, in compari-
son with over one-third of Caucasian re-
spondents. Similarly, approximately one-
half of minority patients would be
concernedabouttheirhealthasaresultof
changes in medication regimens in com-
parison with 22% of Caucasian patients.
Latinos and African Americans were also
more likely to voice reluctance to adding
medications. In adjusted analyses, this
was only found to be signiﬁcant for Afri-
can Americans. Patients who expressed a
concern regarding the use of medications
were more likely to express reluctance to
adding medications.
Our ﬁndings have implications for
the ﬁeld of health disparities in diabetes
care. The basic ﬁnding of ethnic differ-
ences in concerns regarding life with
medications suggests that the everyday
experiences of living with diabetes treat-
mentsare,onaverage,experienceddiffer-
ently by ethnic groups. These differences
inmedicationconcernsmaycontributeto
differences in perceived quality of life re-
lated to diabetes (23). Ethnic differences
in perception will require additional
study to determine their origins and to
clarify their implications for long-term
treatment adoption and disparities in
care.
It is important to note that many of
theconcernsandattitudesrelatedtomed-
ications were shared among all patients.
Patients of ethnic minorities were more
likely to express concerns regarding cur-
rent and future medications, but many
Caucasian patients also shared these con-
cerns. Concerns regarding the physical
and logistical burdens of managing mul-
tiple medications were quite prevalent
throughoutthepopulationandareclearly
important to acknowledge with patients
before intensifying or altering medication
regimens. We found that the experience
of pain or discomfort with the use of cur-
rentoralmedicationswasanindependent
predictor of reluctance to add more med-
ications. It should be noted that the ma-
jority of patients within each racial/ethnic
subgroup were willing to take additional
medication, including insulin, if advised
to do so by their health care providers.
These results are important reminders
that it is important for providers to ap-
proach patients as individuals and elicit
concerns about current and future medi-
cations from patients irrespective of race/
ethnicity. It may be possible to
acknowledge medication concerns while
also intensifying diabetes care through a
shared decision-making approach to
treatment decisions (24).
There are some limitations to this
study. Our recruitment rate was low,
which is likely related to our attempt to
recruit patients irrespective of frequency
ofpriorvisitstoaphysician.Wespeculate
that nonrespondents were less frequent
attendees of clinic and potentially less ad-
herent to medical therapies than respon-
dents. If that is the case, our ﬁndings
likely underestimate the level of concern
about life with medications among pa-
tients with diabetes. A related limitation
Table 3—Adjusted analyses of concerns about medications by race/ethnicity, adjusted comparisons in adults with type 2 diabetes from
Chicago-area clinics, 2004–2006*
African American
vs. Caucasian
Latino vs.
Caucasian
Statements reﬂecting medication concerns (likelihood of responding afﬁrmatively)
I worry about side effects from my medications. 1.32 (0.91–1.92) 2.92 (1.83–4.64)
I worry about becoming dependent on my medications. 1.57 (1.09–2.28) 2.90 (1.83–4.58)
I worry about the expense of my medications or glucose-monitoring supplies. 0.93 (0.64–1.34) 1.84 (1.16–2.93)
If my doctor asked me to change my medication regimen, it would disrupt my daily routine. 1.24 (0.75–2.05) 1.78 (1.01–3.12)
If my doctor asked me to change my medication regimen, it would make me worry more
about my health. 2.29 (1.52–3.45) 3.98 (2.46–6.44)
I worry about switching from name brand to generic drugs. 3.29 (2.06–5.26) 2.12 (1.21–3.73)
Willingness to take more medications or insulin (likelihood of responding “No”)
If your doctor told you that you would beneﬁt from taking more medications, would you be
willing to take more? 2.53 (1.35–4.72) 1.48 (0.69–3.15)
If your doctor told you that you would beneﬁt from taking insulin, would you be willing to
take insulin? 1.59 (0.94–2.70) 1.15 (0.60–2.21)
DataareOR(95%CI).*Eachlogisticregressionmodeladjustedforsex,education(highschoolgraduate),income(10,000USD/year),anddurationofdiabetes.
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tientswhomwesurveyedmaynotberep-
resentative of all patients with diabetes.
The surveyed patients all had physicians
that granted us permission to recruit
them; the majority of subjects had health
insurance and prescription drug cover-
age. In addition, our Spanish-speaking
Latino patients all saw physicians who
spoke Spanish. Given known disparities
in insurance coverage and access to pro-
viders, it is likely that the degree of health
disparitiesinthissampleandtheextentof
racial/ethnic differences in responses to
questions might be less pronounced than
in a population-based study. Nonethe-
less, we still found important disparities
in risk factor control and important dif-
ferences in medication concerns. It is also
important to recognize that the ethnic
group assignment in our sample reﬂects
the speciﬁc ethnic mix of Chicago neigh-
borhoods that composed our clinical
sites. The makeup of the same ethnic
group categories may differ in other parts
of the city, state, and country. Our study
ﬁndings also reﬂect the views of patients
before the publication of reports regard-
ing the potential risks associated with
very intensive glucose control. Current
concerns about quality of life with diabe-
tes-relatedmedicationsmaybeevenmore
widespread than we have found.
Our study provides insights into how
reported concerns regarding diabetes-
related medications vary across racial/
ethnic groups. However, it remains
unclear whether these concerns and per-
ceptions regarding medications are at the
root of observed disparities in diabetes
care and outcomes (25). Longitudinal
studies that help to test the association
between medication concerns with inter-
mediate outcomes after adjusting for dia-
betes severity will be valuable to
addressing this critical question in diabe-
tes health disparities research.
Acknowledgments— This study was sup-
ported by a National Institute of Aging Career
Development Award to E.S.H. (K23-
AG021963), a National Institute of Diabetes
and Digestive and Kidney Diseases Diabetes
Research and Training Center Grant to
S.E.S.B., E.S.H., and D.O.M. (P60 DK20595),
a Centers for Disease Control and Prevention
Potential Extramural Project Grant to E.S.H.,
S.E.S.B., N.T., E.F., B.E., and D.O.M. (U36-
CCU319276), and the Chicago Center of Ex-
cellence in Health Promotion Economics
GranttoE.S.H.andD.O.M.(P30-CD000147).
No potential conﬂicts of interest relevant to
this article were reported.
References
1. Carter JS, Pugh JA, Monterrosa A: Non-
insulin-dependent diabetes mellitus in
minoritiesintheUnitedStates.AnnIntern
Med 125:221–232, 1996
2. Lanting LC, Joung IM, Mackenbach JP,
LambertsSW,BootsmaAH:Ethnicdiffer-
ences in mortality, end-stage complica-
tions, and quality of care among diabetic
patients:areview.DiabetesCare28:2280–
2288, 2005
3. Lustman PJ, Anderson RJ, Freedland KE,
de Groot M, Carney RM, Clouse RE: De-
pression and poor glycemic control: a
meta-analytic review of the literature. Di-
abetes Care 23:934–942, 2000
4. Emanuele N, Sacks J, Klein R, Reda D,
Anderson R, Duckworth W, Abraira C;
the Veterans Affairs Diabetes Trial Group:
Ethnicity, race, and baseline retinopathy
correlates in the Veterans Affairs Diabetes
Trial. Diabetes Care 28:1954–1958, 2005
5. Harris MI, Klein R, Cowie CC, Rowland
M, Byrd-Holt DD: Is the risk of diabetic
retinopathy greater in non-Hispanic
blacks and Mexican Americans than in
non-Hispanic whites with type 2 diabe-
tes? A U.S. population study. Diabetes
Care 21:1230–1235, 1998
6. NationalCenterforHealthStatistics:Age-
adjusted death rates for diabetes, by race
and sex: United States, 1979–2006.
MMWR Recomm Rep 57:855, 2008
7. Department of Health and Human Ser-
vices: Healthy People 2010: Understanding
and Improving Health. Washington, DC,
U.S. Govt. Printing Ofﬁce, 2000
8. American Diabetes Association: Stan-
dards of medical care for patients with di-
abetes mellitus. Diabetes Care 25(Suppl.
1):S33–S49, 2002
9. Steinbrook R: Patients with multiple
chronic conditions: how many medica-
tions are enough? The N Engl J Med 338:
1541–1542, 1998
10. Murray MD, Kroenke K: Polypharmacy
and medical adherence. J Gen Intern Med
16:137–139, 2001
11. Grant RW, Pirraglia PA, Meigs JB, Singer
DE: Trends in complexity of diabetes care
in the United States from 1991 to 2000.
Arch Intern Med 164:1134–1139, 2004
12. Saydah SH, Fradkin JE, Cowie CC: Poor
control of risk factors for vascular disease
among adults with previously diagnosed
diabetes. JAMA 291:335–342, 2004
13. Heisler M, Faul JD, Hayward RA, Langa
KM, Blaum C, Weir D: Mechanisms for
racial and ethnic disparities in glycemic
control in middle-aged and older Ameri-
cans in the health and retirement study.
Arch Intern Med 167:1853–1860, 2007
14. VijanS,HaywardRA,RonisDL,HoferTP:
The burden of diabetes therapy: implica-
tions for the design of effective patient-
centered treatment regimens. J Gen Intern
Med 20:479–482, 2005
15. Folstein MF, Folstein SE, McHugh PR:
“Mini-mental state”: a practical method
for grading the cognitive state of patients
for the clinician. J Psychiatr Res 12:189–
198, 1975
16. Neumann PJ, Goldie SJ, Weinstein MC:
Preference-based measures in economic
evaluation in healthcare. Annu Rev Public
Health 21:587–611, 2000
17. RussellLB,GoldMR,SiegelJE,DanielsN,
Weinstein MC: The role of cost-effective-
nessanalysisinhealthandmedicine.JAm
Med Assoc 276:1172–1177, 1996
18. BoyerJG,EarpJA:Thedevelopmentofan
instrument for assessing the quality of life
ofpeoplewithdiabetes:Diabetes-39.Med
Care 35:440–453, 1997
19. Fitzgerald JT, Davis WK, Connell CM,
HessGE,FunnellMM,HissRG:Develop-
ment and validation of the Diabetes Care
Proﬁle. Eval Health Prof 19:208–230,
1996
20. Huang ES, Gorawara-Bhat R, Chin MH:
Self-reported goals of older patients with
type 2 diabetes mellitus. J Am Geriatr Soc
53:306–311, 2005
21. Ware JEJ, Kosinski M, Keller SD: SF-12:
How to Score the SF-12 Physical and Mental
Health Summary Scales. Boston, Massa-
chusetts, The Health Institute, New En-
gland Medical Center, 1995
22. Charlson ME, Pompei P, Ales KL, Mac-
Kenzie CR: A new method of classifying
prognostic comorbidity in longitudinal
studies: development and validation.
J Chronic Dis 40:373–383, 1987
23. HuangES,BrownSE,EwigmanBG,Foley
EC, Meltzer DO: Patient perceptions of
quality of life with diabetes-related com-
plications and treatments. Diabetes Care
30:2478–2483, 2007
24. MontoriVM,GafniA,CharlesC:Ashared
treatment decision-making approach be-
tween patients with chronic conditions
and their clinicians: the case of diabetes.
Health Expect 9:25–36, 2006
25. Jackevicius CA, Li P, Tu JV: Prevalence,
predictors,andoutcomesofprimarynon-
adherence after acute myocardial infarc-
tion. Circulation 117:1028–1036, 2008
Racial/ethnic differences in medication concerns
316 DIABETES CARE, VOLUME 32, NUMBER 2, FEBRUARY 2009